基-葡萄糖改善了刺激性肠综合征的重要病理生理特征
Caroline Valibouze1, Caroline Dubuquoy2, Philippe Chavatte3
1Department of Digestive Surgery and Transplantation, Lille University, Lille 59037, France.
World journal of gastroenterology
|May 1, 2024
概括
基-葡萄糖 (CG) 为刺激性肠综合征 (IBS) 提供了一种新的治疗策略. 这种益生菌通过调节关键基因和结合微生物毒素来减少内脏疼痛和炎症,显示出IBS管理的希望.
科学领域:
- 胃肠病学 胃肠病学
- 营养科学 营养科学
- 分子生物学分子生物学
背景情况:
- 刺激性肠综合征 (IBS) 是一种普遍的疾病,有效治疗方法有限.
- 丁-葡萄糖 (CG),一种新的饮食益生菌,是安全的人类消费.
- 临床前研究评估了CG在解决IBS病理生理学的潜力.
研究的目的:
- 评估CG在内脏镇痛和减少肠道炎症方面的疗效.
- 为了研究CG对肠道屏障功能的影响.
- 开发CG互动的计算分子模型.
主要方法:
- 在使用结直肠膨胀 (CRD) 和TNBS诱导的老鼠中,模拟了内脏疼痛和过敏症.
- 在患有DSS诱导的大肠炎的小鼠中评估了抗炎作用.
- 细胞测试 (HT-29) 通过实时PCR评估CG对疼痛,炎症和屏障基因的影响.
- 用分子建模和模拟来分析CG与微生物脂质的相互作用.
主要成果:
- CG耐受性很好,没有引起不良反应.
- 在动物模型中,CG显著降低了内脏疼痛感知和炎症.
- 在减轻疼痛方面,CG表现出高于或与黄醇相当的疗效.
- 分子机制包括阿片类和大麻素受体和IL-10的上调,以及IL-1b和IL-8的下调.
- 通过对特定的基因进行上调,CG增强了肠道屏障功能.
- 分子建模揭示了CG能够化微生物致病性脂质,如LPS和LTA.
结论:
- 基-葡萄糖 (CG) 有效地减少内脏疼痛和肠道炎症.
- CG通过调节参与疼痛和炎症途径的关键基因而起作用.
- CG对微生物产品的直接结合为IBS提供了一个新的治疗机制.
相关概念视频
Irritable Bowel Syndrome I: Introduction
272
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
272
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Chronic Bowel Disorders: Introduction
446
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
446
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
157
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
157
Irritable Bowel Syndrome III: Medical and Nursing Management
197
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
197


